Results 31 to 40 of about 1,142,872 (298)

EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

open access: yesArquivos de Gastroenterologia, 2017
BACKGROUND There is evidence that shows that calcineurin inhibitors may be useful for the treatment of severe ulcerative colitis. However, evidence regarding the efficacy of tacrolimus for remission induction in this setting is scarce.
Juan LASA, Pablo OLIVERA
doaj   +1 more source

Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience [PDF]

open access: yesIntestinal Research, 2020
Background/Aims Exclusive enteral nutrition (EEN) is recommended for induction of remission in pediatric Crohn’s disease (CD). However, it is not currently recommended for inducing remission in adults.
Ajit Sood   +7 more
doaj   +1 more source

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

open access: yesHaematologica, 2016
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia.
Paul Ferguson   +11 more
doaj   +1 more source

Clinical Profile and Induction Outcome of Children with T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma

open access: yesPakistan Armed Forces Medical Journal, 2022
Objective: To study the clinical profile and induction outcome in children diagnosed with T-cell acute lymphoblastic leukaemia and lymphoblastic lymphoma. Study Design: Cross-sectional study.
Awais Arshed   +5 more
doaj   +1 more source

Probiotics for induction of remission in ulcerative colitis

open access: yesCochrane Database of Systematic Reviews, 2020
Ulcerative colitis is an inflammatory condition affecting the colon, with an annual incidence of approximately 10 to 20 per 100,000 people. The majority of people with ulcerative colitis can be put into remission, leaving a group who do not respond to first- or second-line therapies.
Kaur, Lakhbir   +5 more
openaire   +3 more sources

Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives

open access: yesClinical Case Reports, 2018
Key Clinical Message The autoimmune polyglandular syndrome is a sequential chain of autoimmune events. Whenever diagnosed, the clinician's target should be induction of remission and if possible hindering its progression especially if associated with ...
Magdy Mohamed Allam   +1 more
doaj   +1 more source

Complete Remission of Acute Myeloid Leukemia in Induction and Consolidation Chemotherapy without Bone Marrow Transplantation: Lessons Learned from Good Presentation Case

open access: yesMajalah Kedokteran Bandung, 2019
Acute myeloid leukemia (AML) is a clinically morphologically and genetically heterogeneous disease with variable responses to therapy. The majority of the patients eventually relapse and succumb to the disease.
Tuti Sri Hastuti   +2 more
doaj   +1 more source

End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India

open access: yesIndian Journal of Rheumatology, 2020
Background: Cyclophosphamide is commonly used along with pulse steroids for induction immunosuppression treatment of severe forms of lupus nephritis (LN).
V Jayaprakash   +7 more
doaj   +1 more source

Antibiotics for induction and maintenance of remission in Crohn's disease [PDF]

open access: yesCochrane Database of Systematic Reviews, 2019
Several antibiotics have been evaluated in Crohn's disease (CD), however randomised controlled trials (RCTs) have produced conflicting results.To assess the efficacy and safety of antibiotics for induction and maintenance of remission in CD.We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register and Clinicaltrials.gov database
Cassandra M, Townsend   +6 more
openaire   +2 more sources

Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]

open access: yes, 2009
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core   +1 more source

Home - About - Disclaimer - Privacy